High, stable and homogenous CD20 expression for efficient rituximab-induced elimination of CD20+ alloreactive donor T cells in the novel CD20/Rituximab 'suicide' system

被引：1
|
作者：
van Meerten, T [1 ]
Claessen, MJ [1 ]
Hagenbeek, A [1 ]
Ebeling, S [1 ]
机构：
[1] Univ Utrecht, Med Ctr, Jordan Lab Hematooncol, Utrecht, Netherlands
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.1750.1750
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1750
引用
收藏
页码：485A / 485A
页数：1
相关论文
共 50 条
  • [31] A novel CD20/CD3 T cell engager designed from Rituximab targeting CD20+cancer with multiple mechanisms.
    Cai, Wenyan
    Dong, Jianbo
    Kankanamalage, Sachith Gallolu
    Titong, Allison
    Shi, Jiadong
    Jia, Zhejun
    Wang, Bo
    Huang, Cai
    Zhang, Jing
    Lin, Jun
    Kan, Steven Z.
    Zhou, Joe
    Liu, Yuc
    CANCER RESEARCH, 2021, 81 (13)
  • [32] MODULATION OF CD20 EXPRESSION ON B CELLS BY ANTI-CD20 ANTIBODIES
    Bellintani, Elaine C.
    de Marco, Renato
    Fantini, Renata
    Valim, Tiago
    Macedo, Denise
    Miyamoto, Yuriko
    Temin, Julia
    Gerbase-DeLima, Maria
    HUMAN IMMUNOLOGY, 2016, 77 : 138 - 138
  • [33] HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells
    Shimizu, R.
    Kikuchi, J.
    Wada, T.
    Ozawa, K.
    Kano, Y.
    Furukawa, Y.
    LEUKEMIA, 2010, 24 (10) : 1760 - 1768
  • [34] HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells
    R Shimizu
    J Kikuchi
    T Wada
    K Ozawa
    Y Kano
    Y Furukawa
    Leukemia, 2010, 24 : 1760 - 1768
  • [35] DIMS compounds enhance rituximab-induced apoptosis of B-CLL cells in vitro through upregulation of CD20 surface expression
    Karlsson, Asa
    von Stein, Petra
    Kimby, Eva
    von Stein, Oliver
    CANCER RESEARCH, 2009, 69
  • [36] Rituximab: A monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris
    El Tal, Abdul Kader
    Posner, Marshall R.
    Spigelman, Zachary
    Ahmed, A. Razzaque
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 55 (03) : 449 - 459
  • [37] MONITORING OF IMMUNOGLOBULIN LEVELS IN RA PATIENTS ON ANTI CD20, RITUXIMAB
    Rice, Ceara
    Ghandi-Das, Dhivya
    Negi, Anurag
    RHEUMATOLOGY, 2020, 59 : 94 - 94
  • [38] Anti CD20 (Rituximab) therapy in refractory pediatric rheumatic diseases
    Reis, J.
    Aguiar, F.
    Brito, I
    ACTA REUMATOLOGICA PORTUGUESA, 2016, 41 (01): : 45 - 55
  • [39] Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101vs. the Type I CD20 Antibodies Rituximab and Ofatumumab
    Herter, Sylvia
    Waldhauer, Inja
    Otz, Tina
    Herting, Frank
    Lang, Sabine
    Nicolini, Valeria
    Roemmele, Michaela
    Friess, Thomas
    Van Puijenbroek, Erwin
    Bacac, Marina
    Weidner, K. Michael
    Gerdes, Christian
    Umana, Pablo
    Klein, Christian
    BLOOD, 2010, 116 (21) : 1601 - 1601
  • [40] In vivo model of novel CD20 suicide gene system.
    Introna, M
    Di Gaetano, N
    Cittera, E
    Golay, J
    BLOOD, 2001, 98 (11) : 421A - 421A
12345